Efficacy, safety, and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary arterial hypertension
Sign Up to like & getrecommendations! Published in 2023 at "Pulmonary Circulation"
DOI: 10.1002/pul2.12198
Abstract: Abstract Treprostinil is a chemically stable analog of prostacyclin, and inhaled treprostinil was developed to deliver the effects directly to the pulmonary vasculature while minimizing systemic side effects. The objective of the study was to… read more here.
Keywords: efficacy; japanese patients; inhaled treprostinil; safety pharmacokinetics ... See more keywords
Inhaled Treprostinil-Prodrug Lipid Nanoparticle Formulations Provide Long-Acting Pulmonary Vasodilation.
Sign Up to like & getrecommendations! Published in 2018 at "Drug research"
DOI: 10.1055/s-0044-100374
Abstract: Treprostinil (TRE), a prostanoid analogue approved in the USA for the treatment of pulmonary arterial hypertension, requires continuous infusion or multiple dosing sessions per day for inhaled and oral routes of administration due to its… read more here.
Keywords: inhaled treprostinil; lipid nanoparticle; tre; treprostinil prodrug ... See more keywords
Comparative evaluation of costs and healthcare resource utilization of oral selexipag versus inhaled treprostinil or oral treprostinil in patients with pulmonary arterial hypertension.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of medical economics"
DOI: 10.1080/13696998.2023.2204769
Abstract: BACKGROUND Pulmonary arterial hypertension (PAH), a rare vasculopathy progressively leading to right heart failure and death, is associated with considerable economic burden. Oral prostacyclin pathway agents (PPAs) like selexipag and treprostinil address an underlying PAH… read more here.
Keywords: oral treprostinil; treprostinil oral; oral selexipag; inhaled treprostinil ... See more keywords
Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis
Sign Up to like & getrecommendations! Published in 2022 at "BMJ Open Respiratory Research"
DOI: 10.1136/bmjresp-2022-001310
Abstract: Introduction Idiopathic pulmonary fibrosis (IPF) greatly impacts quality of life and eventually leads to premature death from respiratory failure. Inhaled treprostinil was associated with improvements in forced vital capacity (FVC) and reduced exacerbations of underlying… read more here.
Keywords: idiopathic pulmonary; pulmonary fibrosis; phase; study ... See more keywords
Inhaled Treprostinil after Initial Clinical Worsening: To Continue or Not to Continue, That’s the Question
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Respiratory and Critical Care Medicine"
DOI: 10.1164/rccm.202112-2721le
Abstract: 1. Hwa V. Human growth disorders associated with impaired GH action: defects in STAT5B and JAK2. Mol Cell Endocrinol 2021;519:111063. 2. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol… read more here.
Keywords: cell; pulmonary alveolar; csf; alveolar proteinosis ... See more keywords
Survival and drug persistence in patients receiving inhaled treprostinil at doses greater than 54 µg (nine breaths) four times daily
Sign Up to like & getrecommendations! Published in 2021 at "Pulmonary Circulation"
DOI: 10.1177/20458940211052228
Abstract: Treprostinil is a prostacyclin approved for the treatment of pulmonary arterial hypertension. Commercial data sets indicate that approximately 20–25% of patients are prescribed a higher dose than the maximum recommended dosage of nine breaths per… read more here.
Keywords: doses bps; bps qid; patients receiving; treprostinil doses ... See more keywords
Inhaled treprostinil vs iloprost: Comparison of adherence, persistence, and health care resource utilization in patients with pulmonary arterial hypertension.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of managed care & specialty pharmacy"
DOI: 10.18553/jmcp.2023.29.1.101
Abstract: BACKGROUND: Pulmonary arterial hypertension (PAH) is associated with a substantial clinical and economic burden. Inhaled prostacyclins are a well-established part of pharmacotherapy for PAH. There are differences between inhaled therapies in the burden imposed by… read more here.
Keywords: persistence; adherence persistence; treprostinil iloprost; inhaled treprostinil ... See more keywords